Skin barrier injury
Conditions
Interventions
Test Group:Use of recombinant collagen dressing
Control group:Medical ice pack
Sponsors
The First Affiliated Hospital, Jinan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Adults between the ages of 18 and 60 (including 60 years old, gender is not limited); 2.Subjects who intend to receive Facial Intense Pulsed Light/Chemical Peel treatment; 3.Subjects who have not taken oral medications such as isotretinoin, glucocorticoids, and tranexamic acid within the past 4 weeks; 4.Subjects are willing to comply with the requirements of the study and provide signed written informed consent, etc; 5.Subjects who can complete the entire follow-up process and answer the questionnaire
Exclusion criteria
Exclusion criteria: 1.Suffering from a disease that seriously affects the healing of wounds; 2.Subjects who work outdoors for long periods of time or require prolonged exposure to sunlight after treatment; 3.People who are allergic or hypersensitive to the ingredients of the products used in the clinical trial; 4.Intense pulsed light, superficial peels or other exfoliative treatments (e.g. fruit acids in concentrations of 10% and less or salicylic acid in concentrations of less than 2%, etc.) on the face within 3 months prior to the screening period or within 2 weeks after the planned procedure; 5.Botulinum toxin, aesthetic treatments, energy-based devices other than photomodulation and intense pulsed light (e.g. lasers, radiofrequency, ultrasound, etc.), dermabrasion, chemical peels of intermediate or greater depth, or other exfoliating treatments (e.g. trichloroacetic acid, carbolic acid, fruit acids of 10% and higher concentration, or salicylic acid of 2% and higher concentration, etc.) to the face within the last 6 months prior to the screening period, or within the last 2 weeks after the planned procedure. 6.Facial skin treated with other temporary fillers such as hyaluronic acid or collagen injection therapy within 12 months prior to screening or within 2 weeks after the planned procedure (refer to exclusion criterion 4 for mesotherapy), or any other permanent or semi-permanent filler filler filler (e.g., calcium hydroxyapatite, poly(L-lactic acid), poly(methylmethacrylate), organosilicone, expanded poly(teflonethylene), poly(caprolactone), autologous lipo-filling, face Lifting (including threading), etc. 7.Those with serious cardiac, hepatic, renal and haematological co-morbidities, complications and serious systemic infections at the time of screening; 8.Subjects with a history of severe psychological and psychiatric disorders; 9.Subjects with cancerous skin lesions or ulceration or inflammation of the skin; 10.Subjects with active herpes simplex at screening; 11.Subjects unwilling to sign the informed consent form; 12.Other conditions that the investigator considers inappropriate to participate in this trial; 13.Women who are planning a pregnancy within 2 weeks of screening, or are breastfeeding or pregnant; 14.Subjects who have participated in other clinical trials within 30 days prior to the screening period;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The repair rate of skin barrier damage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin Roughness Scale;Water content of stratum corneum, Skin elasticity, Trans Epidermal Water Loss(TEWL);Objective index mesured by VISIA;VAS Assessment;Composite scale score reflecting temporary improvement in dry skin and dull complexion;Incidence of adverse events and serious adverse events; | — |
Countries
China
Contacts
Public ContactLiu Hongwei
The First Affiliated Hospital, Jinan University
Outcome results
None listed